Details of the Drug

General Information of Drug (ID: DM6D30Q)

Drug Name
TAK-341
Indication
Disease Entry ICD 11 Status REF
Multiple system atrophy 8D87.0 Phase 2 [1]
Drug Type
Antibody
Cross-matching ID
TTD ID
DA85YQ

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Synuclein alpha (SNCA) TT08OSU SYUA_HUMAN Not Available [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Multiple system atrophy
ICD Disease Classification 8D87.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Synuclein alpha (SNCA) DTT SNCA 1.04E-01 -0.26 -0.33
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 ClinicalTrials.gov (NCT05526391) A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy. U.S.National Institutes of Health.
2 Preclinical development of a high affinity alpha-synuclein antibody, MEDI1341, that can enter the brain, sequester extracellular alpha-synuclein and attenuate alpha-synuclein spreading in vivo. Neurobiol Dis. 2019 Dec;132:104582.